Accelerating Drug Discovery using AI/ML

pepAI predicts novel and diverse molecules accurately and accelerates the pre-clinical discovery

a)Ultra large virtual screening b)Agnostic to therapies and targets(human, bacterial, viral) c)De-novo molecules – novel IP with desired properties

  • Antimicrobial compound/strategy

  • Bacteria
  • Viruses
  • Fungi
  • Yeasts
  • Parasites

  • Human
  • Veterinary
  • AgriFood

Development stage:
  • Development
  • Validation

  • Company

  • Co-develop, Outsource, Joint Venture

Funding organisation:
  • OTHER / NA

Infectious disease area:
  • UTI
  • STI
  • BSI
  • RTI
  • GII
  • SSTI
  • CNSI
  • IAI
  • SSI

Geographic origin:
  • Eurasia

Biotech or Pharma companies with strong biology capabilites seeking partners for HIT identification, Lead generation and lead optimization of novel chemical scaffolds for their protein targets.

Peptris is an AI/ML company creating a versatile AI platform (pepAI) to enhance efficiencies by 10x or more across the drug discovery cascade.

pepAI can scan over a 100Million molecules for diverse applications including – activity prediction on mutated protein in drug resistant organisms thus accelerating drug discovery for AMR

What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!